Abstract
Stage III-N2 non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and requires multimodality management. Neoadjuvant therapy is indicated when upfront surgery is difficult with the aim of tumor shrinkage. Trastuzumab deruxtecan (i.e., DS-8201) is an emerging antibody-drug conjugate (ADC) which four topoisomerase I inhibitors are linked to a HER2-targeting antibody. Prior study has shown a 55% objective response rate (ORR) in previous treated metastatic HER2-mutant NSCLC with durable effect.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
